Blog / News

November 18, 2021

The University of New South Wales Sydney (UNSW) & National Drug and Alcohol Research Centre (NDARC) recently invited Dr. Steven Shoptaw to lecture at a collaborative seminar titled, ASCEND: Therapeutic Interventions for Methamphetamine Dependence. Methamphetamine dependence is a growing public health concern in Australia and many parts of the world. There are currently no approved pharmacotherapies for its treatment, but researchers have been evaluating potentially effective medications as possible treatment options. The ASCEND program (Advancing…...... Read More

November 3, 2021

Dr. Shoptaw was given the honor to present a talk, ‘Medications as Foundation for Stimulant Use Disorder Treatment: Is it Time?’, at this year’s annual Eric D. Hadar Distinguished Lecture at the Columbia University Department of Psychiatry. Since its inception in 2016, the Eric D. Hadar Distinguished Lecture series has broadened the discussion and understanding of current research findings related to substance use disorders and their available treatment options. Columbia’s Division of Substance Use Disorders…...... Read More

March 1, 2021

Q2i is a digital health company that develops technology designed to improve treatment for Substance Use Disorder (SUD). OARS technology is utilized by Medication-Assisted Treatment (MAT) program providers, an approach that combines medication (i.e. methadone and buprenorphine) with counseling and behavioral therapies to reduce and treat Opioid Use Disorder (OUD). The application developed by Q2i features a healthcare team portal along with a patient mobile application that allows providers to examine real time reporting and…...... Read More

February 16, 2021

As you may have read in our annual report, CBAM is preparing to go mobile! We are procuring a mobile clinic equipped with two rooms that will allow us to bring addiction treatment and HIV prevention directly to those most in danger of opioid overdose. This new research project is led by our own Dr. Shoptaw and coordinated through the HIV Prevention Trials Network with collaborating sites in Houston, Pittsburgh, Washington DC, and the Bronx.…...... Read More

February 11, 2021

Dr. Madhukar Trivedi recently presented the paper featured on The New England Journal of Medicine titled “Naltrexone plus Bupropion in Methamphetamine Use Disorder” during the Biweekly CTN Big South/West Node Journal Club. The Journal Club promotes an educational environment where colleagues can discuss and evaluate academic literature and identify new research methods or findings in their respective fields. To view the 1/27/21 Journal Club session click here....... Read More

January 22, 2021

Dr. Shoptaw recently co-authored a paper in The New England Journal of Medicine, titled “Naltrexone plus Bupropion in Methamphetamine Use Disorder.” Currently, there is no medication approved by the Food and Drug Administration (FDA) for the treatment of methamphetamine use disorder. In the paper, Dr. Shoptaw and co-authors discuss a clinical trial that examined two drugs-Naltrexone and Bupropion-used in combination to help those with methamphetamine use disorder avoid relapse. Bupropion is a stimulant like anti-depressant…...... Read More

January 7, 2021

2021 NIDA Summer Research Internship Program Call for Applications- Application Deadline: February 12, 2021. Substance abuse and addiction research internship opportunity: The NIDA Summer Research Internship Program introduces undergraduate students, with a goal of increasing underrepresented groups in biomedical and behavioral sciences, to substance abuse and addiction research. Through this program, undergraduate students age 18 years and older, conduct substance abuse and addiction research by participating in internships with NIDA funded scientists at universities across…...... Read More

November 16, 2020

Interim Analysis Shows High Efficacy Rate for the mRNA-1273 Vaccine It was announced today that the Moderna COVID-19 vaccine trial “has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%.” This is based on the first interim analysis of the data, conducted by an independent, NIH-appointed Data Safety Monitoring Board. Of the 30,000 participants enrolled in the trail, one half received the vaccine and one half received…...... Read More

August 25, 2020

The UCLA Vine Street Clinic has begun enrollment in the Moderna trial. This is one of several studies seeking a vaccine for SARS-CoV-2, also known as COVID-19. The purpose of this study is to test Moderna’s vaccine candidate (mRNA-1273) to see if it can prevent illness in people who are exposed to the SARS-CoV-2 virus in their everyday lives. This vaccine is not made from the SARS-CoV-2 virus. It is made from messenger ribonucleic acid…...... Read More

July 23, 2020

The National Institute on Drug Abuse (NIDA) has awarded a 5-year, $7.5million grant to fund the Big South/West Node of the Clinical Trials Network (CTN). Steven Shoptaw, PhD, Director of the Center for Behavioral & Addiction Medicine and Professor and Vice Chair of Research for the UCLA Department of Family Medicine, will share leadership of the node with Madhukar H. Trivedi, MD, Director of the Center for Depression Research and Clinical Care and Professor of…...... Read More

June 28, 2020

  On April 30, Dr. Keith Heinzerling was quoted in an article about rising alcohol sales during the pandemic. The isolation and stress caused by stay-at-home orders and the easy availability of alcohol through home delivery services has made it increasingly difficult for people in recovery to maintain their sobriety. However, Dr. Heinzerling noted that “Avoiding alcohol and drug use will help to keep you and your immune system as healthy as possible to avoid…...... Read More

June 28, 2020

On April 16, CBAM’s Dr. Steve Shoptaw and colleagues published a Collective Call to Action for HIV/AIDS Community-Based Collaborative Science in the Era of COVID-19 in the journal AIDS and Behavior. Their goal: to ensure that our response to the COVID-19 crisis does not erode the significant gains made in HIV treatment and prevention. We must find ways to address COVD-19, to ensure the health and safety of our staff and our patients, while also…...... Read More

June 28, 2020

On April 15, our paper “Trajectories of viral suppression in people living with HIV receiving coordinated care: Differences by comorbidities” was highlighted in the New England Journal of Medicine’s (NEJM) Journal Watch, where NEJM physician editors select and summarize important research, medical news, drug information, public health alerts and clinical guidelines across 12 specialties. The paper, led by Dr. Michael Li, assessed obstacles to improved HIV-cascade care for patients enrolled in the LA County Public…...... Read More

February 20, 2020

CBS reported on their February, 19, eleven o’clock nightly news broadcast that three student deaths at USC which occurred this past Fall were recently found to be the result of accidental overdoses of fentanyl. Click here to watch the full 4-minute segment including an interview with CBAM Executive Director, Dr. Steven Shoptaw....... Read More

November 5, 2019

Our very own Dr. Shoptaw recently co-authored a paper in the Lancet’s Series on Drug Use, titled “Responding to global stimulant use: challenges and opportunities.” In the paper, Dr. Shoptaw and co-authors discuss the rising problem of stimulant use, with an emphasis on amphetamine and cocaine use. The increase in use of this class of drugs requires specific, tailored responses to reduce the harm they bring to communities, both fatal and non-fatal, such as poor…...... Read More

September 16, 2019

The goal of the study was to learn about the experiences of PrEP-related stigma among Black and Latina transgender women (TW) who are using PrEP in Los Angeles County. Our findings revealed that participants experience HIV stigma directly related to their identity as TW, due to the high prevalence in the population. This context helped us to better understand the experiences of stigma related to their PrEP use. The three themes surrounding PrEP stigma included:…...... Read More

August 26, 2019

The UCLA Vine Street Clinic in partnership with the UCLA CARE Center attended the 4th Annual DTLA Proud Festival. Research participants from both centers were given free admission tickets to this year’s event, as a token of our appreciation for their efforts and contribution to research....... Read More

January 30, 2019

UCLA Addiction Medicine Fellowship is Accepting Applications! The UCLA Department of Family Medicine is currently accepting applications for its one-year clinical fellowship in Addiction Medicine. The overall educational goals for the fellowship program will be obtained through longitudinal continuity of care experiences, clinical core rotations, program specific rotations, elective rotations and scholarly activities. For more information or to download the application, visit https://www.uclahealth.org/family-medicine/addiction-medicine....... Read More

January 7, 2019

2019 NIDA Summer Research Internship Program Call for Applications- Application Deadline: February 11, 2019. Substance abuse and addiction research internship opportunity: The NIDA Summer Research Internship Program introduces undergraduate students, with a goal of increasing underrepresented groups in biomedical and behavioral sciences, to substance abuse and addiction research. Through this program, undergraduate students age 18 years and older, conduct substance abuse and addiction research by participating in internships with NIDA funded scientists at universities across…...... Read More

December 20, 2018

CBAM has been working for decades on issues surrounding substance use and HIV. Through our research, we seek to better understand the impact of substance use on HIV transmission and progression and on general health. In a recent study published in the journal Drug and Alcohol Dependence, our researchers compared gay and bisexual men with methamphetamine dependence to matched controls and found that death rates were three times higher in methamphetamine-dependent individuals than in the…...... Read More

December 19, 2018

You are cordially invited to the University of Southern California’s Institute for Addiction Science’s Speaker Series talk by Dr. Stephen T. Higgins, titled “Changing Drug Use and Other Health-related Behavior in Vulnerable Populations.” Stephen T. Higgins, Ph.D., is Director of the University of Vermont’s (UVM) Vermont Center on Behavior and Health (VCBH). The Center is supported by multiple federal grants including the Centers of Biomedical Research Excellence (COBRE) Award from NIGMS, and the Tobacco Centers…...... Read More

December 12, 2018

Last month, Dr. Shoptaw had the distinct pleasure of moderating a Los Angeles World Affairs Council Book Event. The event, which took place on November 28 in Culver City, allowed for an energetic discussion regarding the opioid epidemic.   From the LAWAC website: “Last year, thousands of Americans died from overdosing on prescription painkillers. The issue, says Guardian journalist and author Chris McGreal, is not just misuse, but over-prescription by doctors and a lack of…...... Read More

November 27, 2018

Today is #GivingTuesday, a global day of giving that kicks off the charitable season. This year, consider making a donation to CBAM. The latest figures from the National Survey on Drug Use and Health indicate what we at CBAM have been seeing for some time – that there are major gaps in treatment for substance users and our most vulnerable continue to be left out. The same is true for HIV prevention and care. CBAM…...... Read More

October 10, 2018

Nic Sheff, author of “Tweak” and David Sheff, author of “Beautiful Boy” were joined Dr. Steven Shoptaw and Dr. Larissa Mooney of UCLA as part of the Friends of Semel screening of the upcoming film “Beautiful Boy” based on the family’s struggle with and recovery from addiction. The movie stars Steve Carell as David and Timothee Chalamet as Nic. After the film, the panel discussed issues of addiction.   Photos courtesy of Reed Hutchingson Photography....... Read More

August 16, 2018

In September 2017, the Drug Policy Alliance organized a conference in Los Angeles in partnership with over a dozen organizations, including the Center for Behavioral and Addiction Medicine (CBAM), titled “Stimulant Use: Harm Reduction, Treatment, and Future Directions.” The conference aimed to bring attention to a large class of drugs that has received inconsistent attention from the media, harm reduction and treatment communities, researchers, and policymakers alike. Los Angeles was chosen for this conference due…...... Read More

August 1, 2018

We’re so excited to see the positive results of this program to assist federally qualified community health centers in the implementation of medication-assisted treatment (MAT) for opioid addiction. CBAM’s Dr. Keith Heinzerling was one of several MAT experts engaged by the program to provide direct coaching assistance to participating health centers. Program highlights include a shift in perspective about addiction and the use of MAT, as well as an increase in the number of patients…...... Read More

April 6, 2018

A word from Dr. Steven Shoptaw: One of the world pioneers in HIV medicine in India was not only a physician scientist and inspiring human being, but apparently also a matchmaker! What is even better, is that Suniti continues to impact our world today when you look at this film trailer: lovesickthefilm.com Those of you privileged to have met Suniti Solomon will experience the same shock and thrill when you see her standing there, in…...... Read More

March 9, 2018

Dr. Shoptaw traveled back to Cape Town, South Africa in February! While there, he met with our team at the University of Cape Town as they finish up a research project looking at the neuroscience behind contingency management for methamphetamine users. He also met with additional faculty at the University of Cape Town to discuss several exciting new research endeavors to expand our global efforts. We aim to bring the innovative, state-of-the-art interventions to Cape…...... Read More

March 1, 2018

UCLA CBAM received a grant of $102,472 from the California Community Foundation to study the links between mental health and biological predictors of health outcomes in a cohort of primarily minority men who have sex with men (MSM) who are HIV positive. This is a population with low rates of viral suppression, a key measure of health outcomes for those affected by HIV. Viral suppression is an indicator, not only of overall health, but of…...... Read More

February 23, 2018

CBAM’s Chris Blades attended the Los Angeles Community College District’s Transgender Summit at Los Angeles Trade Tech. The purpose of the summit was to share information, resources, and ideas to support transgender/gender-nonconforming individuals at the community colleges within Los Angeles County. Sessions at this summit focused on a variety of issues including internalized transphobia, how to empower LGBTQ youth, as well as cultural competency for businesses....... Read More

February 9, 2018

Staff from the UCLA Vine Street Clinic recently participated in a mural design project with the Hollywood Police Activities League (PAL) and Arts Bridging the Gap. PAL is a community-based program that provides youth with positive alternatives to drugs and crime. Arts Bridging the Gap also supports youth by linking together artists, educators, and community organizations to create meaningful and impactful art in the community. Our staff spent an afternoon brainstorming ideas with members of…...... Read More

November 20, 2017

We cordially invite you to join the webinar introducing the Substance Use Measure Identification (SUMI) Tool. Dr. Shoptaw, Executive Committee Liaison for the Substance Use Scientific Committee SUSC worked in collaboration with Drs. Steffanie Strathdee and Nabila El-Bassel, and the SUSC to develop this tool to help researchers efficiently identify appropriate biomarker and behavioral survey measures to assess substance use in the context of HIV. Dr. Shipeng Chen designed and developed this tool. This collaboration,…...... Read More

June 28, 2017

The UCLA Vine Street Clinic team is excited to be a part of on-going research testing the effectiveness of long-acting forms of HIV prevention medications. The current option, Truvada™ for PrEP (pre-exposure prophylaxis) requires that people take a pill every day, which can present barriers for many. There are two studies currently seeking to expand the options available for PrEP. The first is the AMP Study (Antibody Mediated Prevention). This is a new approach to…...... Read More

June 21, 2017

CBAM would like to congratulate Dr. Walter Ling, 2017 recipient of the Nathan B. Eddy Memorial Award, acknowledging outstanding research efforts that have advanced knowledge of drug dependence. Dr. Ling’s research provided key information that led to the approval of many of the existing medication options for treating drug dependence. His illustrious career spans decades, covering groundbreaking research into the treatment of opioid, cocaine, and methamphetamine use disorders. His work has expanded to 15 countries…...... Read More

April 20, 2017

Dr. Wilbert Jordan, Medical Director of the OASIS Clinic at Martin Luther King Jr. Outpatient Center and Associate Professor, Internal Medicine at Charles R. Drew University of Medicine and Science (CDU), recently announced that the OASIS Clinic has initiated biomedical services to prevent HIV. Pre-exposure Prophylaxis (PrEP) is one of the newest tools available in the HIV prevention toolbox. PrEP is a way for people who don’t have HIV but who are at very high…...... Read More

February 1, 2017

CBAM works at the intersection of academia and community. We frequently publish findings from our research and collaborative projects with top scientific journals. Summaries of those articles are made available on our website so that everyone can see the fruits of our labor. In 2016, we covered a range of topics from HIV Stigma to integrating substance use care in primary health care settings. Read more here: http://www.uclacbam.org/about-us/publicationsresources/....... Read More

January 6, 2017

This lovely card arrived at the UCLA Vine Street Clinic over the holidays. It came from a patient who screened for one of our methamphetamine clinical trials. She was ultimately considered ineligible because of a medical condition, but the diagnosis she received here, prompted her to see her primary care physician. She wrote to let us know that, not only is her condition now under control, but that “My visits to your clinic were the…...... Read More

December 22, 2016

Greetings from Vietnam! Dr. Shoptaw attended the workshop “Amphetamine-Type Stimulants (ATS) Workshop”, where he presented on “The Use of ATS and the Risk of HIV Infection in the United States: Some Models of Intervention.” Pictured here is Dr. Shoptaw (right) with Professor Robert Ali (left) from Australia and Professor Apinum Aramrattana (center) from Thailand....... Read More

December 21, 2016

  Although December signals the end of the year, we have been quite busy at CBAM. Members of the CHIPTS team at CBAM joined with community and government agencies to co-sponsor two local events. The City of Los Angeles AIDS Coordinator’s Office, in collaboration with several key community partners, hosted a conference on “Addressing the Intersection of Racism & HIV.” This event discussed important topics such as the role of mass incarceration in the spread…...... Read More

September 29, 2016

Yesterday, a former research patient stopped by our clinic to drop off this cake as a token of appreciation, reporting 7 months of sobriety and counting. This is why we do the work we do at CBAM....... Read More

About

CBAM is a multidisciplinary center that seeks to advance the prevention and treatment of chronic illnesses, especially in communities with health disparities. As part of the UCLA Department of Family Medicine, CBAM works at the intersection of academia and community with a focus on treating addictions and preventing the spread of HIV.

© The UCLA Center for Behavioral & Addiction Medicine (CBAM). All Rights Reserved.